The trial is a multicenter, multinational trial that is assessing the safety and efficacy of the drug in combination with prednisone as second-line chemotherapy in patients with the condition, which is the most common cancer among men in the US and Europe.
More than 200 clinical sites in fifteen countries have enrolled 912 patients to the trial. A number of additional patients are in screening, and the company says that it will allow those patients to complete the process and either be randomized into the trial or disqualified, in accordance with the trial protocol.
“The rapid accrual rate of the SPARC trial supports the need for effective second-line chemotherapy treatments for hormone-refractory prostate cancer patients,” said Dr Bernd Seizinger, CEO. “We are thus committed to completing the study and moving forward in the registration process as expeditiously as possible.”